Stanley B Cohen

Summary

Affiliation: Radiant Research
Country: USA

Publications

  1. ncbi Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
    Stanley Cohen
    Department of Rheumatology, St Paul Medical Center, Dallas, Texas 75235, USA
    Arthritis Rheum 46:614-24. 2002
  2. ncbi The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis
    Stanley B Cohen
    Radiant Research Dallas, TX 75275, USA
    Rheum Dis Clin North Am 30:365-80, vii. 2004
  3. ncbi Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
  4. ncbi Updates from B Cell Trials: Efficacy
    Stanley B Cohen
    University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas 75235, USA
    J Rheumatol Suppl 77:12-7. 2006
  5. ncbi Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases
    Stanley Cohen
    St Paul University Hospital, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235, USA
    Arthritis Rheum 55:15-8. 2006
  6. ncbi Bringing the clinical experience with anakinra to the patient
    S B Cohen
    St Paul University Medical Center, Dallas, Texas, USA
    Rheumatology (Oxford) 42:ii36-40. 2003
  7. ncbi Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy
    S B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Rheumatology (Oxford) 43:704-11. 2004
  8. ncbi An update on bisphosphonates
    Stanley B Cohen
    Radiant Research, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235, USA
    Curr Rheumatol Rep 6:59-65. 2004
  9. pmc Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas, USA
    Ann Rheum Dis 69:1158-61. 2010
  10. doi Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
    Stanley B Cohen
    Metroplex Clinical Research, Dallas, Texas 75235, USA
    Arthritis Rheum 60:335-44. 2009

Detail Information

Publications31

  1. ncbi Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
    Stanley Cohen
    Department of Rheumatology, St Paul Medical Center, Dallas, Texas 75235, USA
    Arthritis Rheum 46:614-24. 2002
    ..To evaluate the efficacy and safety of anakinra in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA)...
  2. ncbi The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis
    Stanley B Cohen
    Radiant Research Dallas, TX 75275, USA
    Rheum Dis Clin North Am 30:365-80, vii. 2004
    ..This article reviews the preclinical, clinical, and postmarketing data on the safety and efficacy of anakinra in the treatment of rheumatoid arthritis and focuses on the pivotal clinical trials that led to FDA approval...
  3. ncbi Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
    ....
  4. ncbi Updates from B Cell Trials: Efficacy
    Stanley B Cohen
    University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas 75235, USA
    J Rheumatol Suppl 77:12-7. 2006
    ..These findings support the hypothesis that B cells play an integral role in the pathogenesis of RA, and this report will review the efficacy results of clinical trials targeting B cells...
  5. ncbi Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases
    Stanley Cohen
    St Paul University Hospital, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235, USA
    Arthritis Rheum 55:15-8. 2006
    ..We welcome reader feedback and ideas for future topics...
  6. ncbi Bringing the clinical experience with anakinra to the patient
    S B Cohen
    St Paul University Medical Center, Dallas, Texas, USA
    Rheumatology (Oxford) 42:ii36-40. 2003
    ....
  7. ncbi Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy
    S B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Rheumatology (Oxford) 43:704-11. 2004
    ..To determine whether patient-reported outcomes may differentiate treatment response better than physician-reported outcomes for rheumatoid arthritis (RA) patients being treated with anakinra...
  8. ncbi An update on bisphosphonates
    Stanley B Cohen
    Radiant Research, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235, USA
    Curr Rheumatol Rep 6:59-65. 2004
    ..Further development of bisphosphonates as adjunctive therapy to reduce bone metastases is in progress, and trials evaluating bisphosphonates as a structure modifying agent in osteoarthritis are nearing completion...
  9. pmc Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas, USA
    Ann Rheum Dis 69:1158-61. 2010
    ..Rituximab inhibited structural damage at 1 year in patients with rheumatoid arthritis (RA) who had had a previous inadequate response to tumour necrosis factor (TNF) inhibitors...
  10. doi Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
    Stanley B Cohen
    Metroplex Clinical Research, Dallas, Texas 75235, USA
    Arthritis Rheum 60:335-44. 2009
    ..To determine the efficacy and safety of pamapimod (a selective inhibitor of the alpha-isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA)...
  11. doi Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas 75235, USA
    Arthritis Rheum 58:1299-309. 2008
    ..The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment...
  12. ncbi Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study
    Edward C Keystone
    Mount Sinai Hospital and the University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 39:2238-46. 2012
    ....
  13. ncbi Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence
    Stanley B Cohen
    The University of Texas Southwestern Medical Center, Office of Continuing Education, 5323 Harry Hines Blvd, Dallas, TX 75390 9059, USA
    J Rheumatol Suppl 81:4-30; quiz 31-4. 2008
    ..In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA...
  14. ncbi B-cell depletion for rheumatic diseases: where are we?
    Stanley B Cohen
    University of Texas Southwestern Medical Center at Dallas, Texas, USA
    MedGenMed 7:72. 2005
    ....
  15. ncbi Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis
    Stanley B Cohen
    St Paul Medical Center, Dallas, Texas, USA
    J Rheumatol 30:225-31. 2003
    ....
  16. ncbi Immune-mediated inner ear disease: 10-year experience
    Shelley S Broughton
    Otolaryngology, University of Texas Southwestern Medical School, Dallas, Texas, USA
    Semin Arthritis Rheum 34:544-8. 2004
    ..Limited information is available regarding clinical features of the disease, disease course, and response to treatment...
  17. pmc A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee
    Stanley B Cohen
    Rheumatology, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75231, USA
    Arthritis Res Ther 13:R125. 2011
    ..The purpose of this two-part study was to evaluate the safety and pharmacokinetics (PK; Part A) and clinical effect (Part B) of AMG 108 in a double-blind, placebo-controlled, multiple-dose study in patients with OA of the knee...
  18. ncbi Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial
    Alan J Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
    J Am Geriatr Soc 52:666-74. 2004
    ..To evaluate the use of starting doses of rofecoxib and nabumetone in patients with osteoarthritis (OA) of the knee...
  19. pmc Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort
    Jeffrey D Greenberg
    New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Am J Med 121:532-8. 2008
    ..The study objective was to investigate responsiveness according to whether patients satisfy eligibility criteria from randomized controlled trials of tumor necrosis factor (TNF) antagonists in a multicentered US cohort...
  20. ncbi Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Arthritis Rheum 50:2264-72. 2004
    ..In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA...
  21. ncbi The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
    Karen E Hansen
    Division of Rheumatology, University of Wisconsin, Madison, Wisconsin, USA
    J Rheumatol 31:1098-102. 2004
    ..To describe the degree of clinical benefit in patients with rheumatoid arthritis (RA) who receive infliximab therapy after lack of efficacy with etanercept...
  22. ncbi Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
    J Bone Miner Res 22:1832-41. 2007
    ..Continued study of denosumab is warranted in the treatment of low BMD in postmenopausal women...
  23. ncbi Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis
    Honghui Zhou
    Clinical Pharmacology and Experimental Medicine, Centocor Research and Development, 200 Great Valley Parkway, Malvern, PA 19355, USA
    J Clin Pharmacol 47:383-96. 2007
    ..0%. Body weight was found to be an important covariate on V(c). Golimumab was generally well tolerated. The pharmacokinetics of golimumab appeared to be linear over the dose range evaluated in this study...
  24. ncbi Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Room 404, Baltimore, MD 21224, USA
    Arthritis Rheum 54:3494-507. 2006
    ....
  25. ncbi Denosumab in postmenopausal women with low bone mineral density
    Michael R McClung
    Providence Portland Medical Center, Portland, Oreg, USA
    N Engl J Med 354:821-31. 2006
    ..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action...
  26. ncbi Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 33:712-21. 2006
    ..Clinical and radiographic responses were evaluated in patients with psoriatic arthritis (PsA) treated for up to 2 years with etanercept...
  27. ncbi Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies
    Dinesh Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati and Veterans Affairs Medical Center, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 52:3030-8. 2005
    ..To examine the effect of folic acid on the efficacy of methotrexate (MTX) treatment in rheumatoid arthritis (RA) at 12 months in 2 phase III randomized controlled trials (RCTs) of leflunomide in which MTX was used as a comparator...
  28. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    ..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment...
  29. ncbi Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus
    Michelle A Petri
    Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA
    Arthritis Rheum 50:2858-68. 2004
    ..To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms...
  30. doi The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road
    Joan M Bathon
    Arthritis Rheum 59:757-9. 2008
  31. ncbi Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial
    Silvano Adami
    Rheumatologic Rehabilitation Unit, University of Verona, Via Santa Maria Crocifissa di Rosa, 37067 Valeggio sul Mincio VR, Italy
    Mayo Clin Proc 80:1278-85. 2005
    ..To evaluate the frequency of upper gastrointestinal (GI) tract adverse events associated with risedronate during two (2-year) randomized, double-blind, parallel-group, placebo-controlled studies...